Ovarian  ||| S:0 E:8 ||| JJ
cancer ||| S:8 E:14 ||| NN
:  ||| S:14 E:16 ||| :
markers  ||| S:16 E:24 ||| NN
of  ||| S:24 E:27 ||| IN
response  ||| S:27 E:36 ||| NN
Despite  ||| S:36 E:44 ||| IN
improved  ||| S:44 E:53 ||| JJ
knowledge  ||| S:53 E:63 ||| NN
regarding  ||| S:63 E:73 ||| VBG
the  ||| S:73 E:77 ||| DT
etiology  ||| S:77 E:86 ||| NN
of  ||| S:86 E:89 ||| IN
ovarian  ||| S:89 E:97 ||| JJ
cancer ||| S:97 E:103 ||| NN
,  ||| S:103 E:105 ||| ,
as  ||| S:105 E:108 ||| RB
well  ||| S:108 E:113 ||| RB
as  ||| S:113 E:116 ||| IN
application  ||| S:116 E:128 ||| NN
of  ||| S:128 E:131 ||| IN
aggressive  ||| S:131 E:142 ||| JJ
surgery  ||| S:142 E:150 ||| NN
and  ||| S:150 E:154 ||| CC
chemotherapy ||| S:154 E:166 ||| NN
,  ||| S:166 E:168 ||| ,
there  ||| S:168 E:174 ||| EX
has  ||| S:174 E:178 ||| VBZ
been  ||| S:178 E:183 ||| VBN
only  ||| S:183 E:188 ||| RB
a  ||| S:188 E:190 ||| DT
modest  ||| S:190 E:197 ||| JJ
change  ||| S:197 E:204 ||| NN
in  ||| S:204 E:207 ||| IN
the  ||| S:207 E:211 ||| DT
mortality  ||| S:211 E:221 ||| NN
statistics  ||| S:221 E:232 ||| NNS
over  ||| S:232 E:237 ||| IN
the  ||| S:237 E:241 ||| DT
last  ||| S:241 E:246 ||| JJ
30  ||| S:246 E:249 ||| CD
years ||| S:249 E:254 ||| NNS
.  ||| S:254 E:256 ||| .
Given  ||| S:256 E:262 ||| VBN
these  ||| S:262 E:268 ||| DT
results  ||| S:268 E:276 ||| NNS
and  ||| S:276 E:280 ||| CC
the  ||| S:280 E:284 ||| DT
evolution  ||| S:284 E:294 ||| NN
of  ||| S:294 E:297 ||| IN
targeted  ||| S:297 E:306 ||| JJ
therapies ||| S:306 E:315 ||| NNS
,  ||| S:315 E:317 ||| ,
there  ||| S:317 E:323 ||| EX
is  ||| S:323 E:326 ||| VBZ
an  ||| S:326 E:329 ||| DT
increasing  ||| S:329 E:340 ||| JJ
need  ||| S:340 E:345 ||| NN
for  ||| S:345 E:349 ||| IN
prognostic  ||| S:349 E:360 ||| NN
and  ||| S:360 E:364 ||| CC
predictive  ||| S:364 E:375 ||| JJ
factors  ||| S:375 E:383 ||| NNS
to  ||| S:383 E:386 ||| TO
stratify  ||| S:386 E:395 ||| VB
patients  ||| S:395 E:404 ||| NNS
for  ||| S:404 E:408 ||| IN
individualized  ||| S:408 E:423 ||| JJ
care ||| S:423 E:427 ||| NN
.  ||| S:427 E:429 ||| .
Many  ||| S:429 E:434 ||| JJ
laboratories  ||| S:434 E:447 ||| NNS
have  ||| S:447 E:452 ||| VBP
also  ||| S:452 E:457 ||| RB
investigated  ||| S:457 E:470 ||| VBD
the  ||| S:470 E:474 ||| DT
specific  ||| S:474 E:483 ||| JJ
individual  ||| S:483 E:494 ||| JJ
biomarkers  ||| S:494 E:505 ||| NNS
correlating  ||| S:505 E:517 ||| VBP
them  ||| S:517 E:522 ||| PRP
with  ||| S:522 E:527 ||| IN
clinicopathologic  ||| S:527 E:545 ||| JJ
characteristics ||| S:545 E:560 ||| NNS
.  ||| S:560 E:562 ||| .
Unfortunately ||| S:562 E:575 ||| RB
,  ||| S:575 E:577 ||| ,
the  ||| S:577 E:581 ||| DT
vast  ||| S:581 E:586 ||| JJ
majorities  ||| S:586 E:597 ||| NN
of  ||| S:597 E:600 ||| IN
these  ||| S:600 E:606 ||| DT
biomarkers  ||| S:606 E:617 ||| NNS
have  ||| S:617 E:622 ||| VBP
not  ||| S:622 E:626 ||| RB
proved  ||| S:626 E:633 ||| VBN
clinically  ||| S:633 E:644 ||| RB
valuable ||| S:644 E:652 ||| JJ
.  ||| S:652 E:654 ||| .
In  ||| S:654 E:657 ||| IN
this  ||| S:657 E:662 ||| DT
article ||| S:662 E:669 ||| NN
,  ||| S:669 E:671 ||| ,
we  ||| S:671 E:674 ||| PRP
review  ||| S:674 E:681 ||| VBP
published  ||| S:681 E:691 ||| VBN
genomic  ||| S:691 E:699 ||| JJ
signatures  ||| S:699 E:710 ||| NNS
including  ||| S:710 E:720 ||| VBG
data  ||| S:720 E:725 ||| NNS
generated  ||| S:725 E:735 ||| VBN
in  ||| S:735 E:738 ||| IN
our  ||| S:738 E:742 ||| PRP$
laboratory  ||| S:742 E:753 ||| NN
for  ||| S:753 E:757 ||| IN
their  ||| S:757 E:763 ||| PRP$
relevance ||| S:763 E:772 ||| NN
.  ||| S:772 E:774 ||| .
Multiple  ||| S:774 E:783 ||| JJ
published  ||| S:783 E:793 ||| JJ
expression  ||| S:793 E:804 ||| NN
profiling  ||| S:804 E:814 ||| NN
articles  ||| S:814 E:823 ||| NNS
were  ||| S:823 E:828 ||| VBD
selected  ||| S:828 E:837 ||| VBN
for  ||| S:837 E:841 ||| IN
review  ||| S:841 E:848 ||| NN
and  ||| S:848 E:852 ||| CC
discussion ||| S:852 E:862 ||| NN
.  ||| S:862 E:864 ||| .
Genomic  ||| S:864 E:872 ||| JJ
studies  ||| S:872 E:880 ||| NNS
were  ||| S:880 E:885 ||| VBD
separated  ||| S:885 E:895 ||| VBN
from  ||| S:895 E:900 ||| IN
those  ||| S:900 E:906 ||| DT
with  ||| S:906 E:911 ||| IN
dichotomized  ||| S:911 E:924 ||| JJ
survival  ||| S:924 E:933 ||| NN
data  ||| S:933 E:938 ||| NNS
and  ||| S:938 E:942 ||| CC
unsupervised  ||| S:942 E:955 ||| JJ
analysis  ||| S:955 E:964 ||| NN
to  ||| S:964 E:967 ||| TO
identify  ||| S:967 E:976 ||| VB
discreet  ||| S:976 E:985 ||| JJ
subsets  ||| S:985 E:993 ||| NN
of  ||| S:993 E:996 ||| IN
tumors  ||| S:996 E:1003 ||| NNS
and  ||| S:1003 E:1007 ||| CC
studies  ||| S:1007 E:1015 ||| NNS
that  ||| S:1015 E:1020 ||| WDT
generated  ||| S:1020 E:1030 ||| VBD
activated  ||| S:1030 E:1040 ||| VBN
pathways ||| S:1040 E:1048 ||| NN
.  ||| S:1048 E:1050 ||| .
The  ||| S:1050 E:1054 ||| DT
identification  ||| S:1054 E:1069 ||| NN
of  ||| S:1069 E:1072 ||| IN
prognostic  ||| S:1072 E:1083 ||| NN
and  ||| S:1083 E:1087 ||| CC
predictive  ||| S:1087 E:1098 ||| JJ
individual  ||| S:1098 E:1109 ||| JJ
biomarkers  ||| S:1109 E:1120 ||| NN
has  ||| S:1120 E:1124 ||| VBZ
been  ||| S:1124 E:1129 ||| VBN
common ||| S:1129 E:1135 ||| JJ
.  ||| S:1135 E:1137 ||| .
Few  ||| S:1137 E:1141 ||| JJ
of  ||| S:1141 E:1144 ||| IN
these  ||| S:1144 E:1150 ||| DT
have  ||| S:1150 E:1155 ||| VBP
been  ||| S:1155 E:1160 ||| VBN
validated ||| S:1160 E:1169 ||| NN
.  ||| S:1169 E:1171 ||| .
Genomic  ||| S:1171 E:1179 ||| JJ
profiles  ||| S:1179 E:1188 ||| NNS
have  ||| S:1188 E:1193 ||| VBP
been  ||| S:1193 E:1198 ||| VBN
obtained  ||| S:1198 E:1207 ||| VBN
that  ||| S:1207 E:1212 ||| IN
distinguish  ||| S:1212 E:1224 ||| JJ
short-  ||| S:1224 E:1231 ||| NN
from  ||| S:1231 E:1236 ||| IN
long-term  ||| S:1236 E:1246 ||| JJ
survivors ||| S:1246 E:1255 ||| NNS
.  ||| S:1255 E:1257 ||| .
The  ||| S:1257 E:1261 ||| DT
relevance  ||| S:1261 E:1271 ||| NN
of  ||| S:1271 E:1274 ||| IN
these  ||| S:1274 E:1280 ||| DT
studies  ||| S:1280 E:1288 ||| NNS
to  ||| S:1288 E:1291 ||| TO
the  ||| S:1291 E:1295 ||| DT
large  ||| S:1295 E:1301 ||| JJ
number  ||| S:1301 E:1308 ||| NN
of  ||| S:1308 E:1311 ||| IN
patients  ||| S:1311 E:1320 ||| NNS
within  ||| S:1320 E:1327 ||| IN
the  ||| S:1327 E:1331 ||| DT
extremes  ||| S:1331 E:1340 ||| NN
remains  ||| S:1340 E:1348 ||| VBZ
unclear ||| S:1348 E:1355 ||| JJ
.  ||| S:1355 E:1357 ||| .
Unsupervised  ||| S:1357 E:1370 ||| JJ
clustering  ||| S:1370 E:1381 ||| JJ
studies  ||| S:1381 E:1389 ||| NNS
of  ||| S:1389 E:1392 ||| IN
ovarian  ||| S:1392 E:1400 ||| JJ
cancers  ||| S:1400 E:1408 ||| NNS
have  ||| S:1408 E:1413 ||| VBP
identified  ||| S:1413 E:1424 ||| VBN
potential  ||| S:1424 E:1434 ||| JJ
subsets  ||| S:1434 E:1442 ||| NN
of  ||| S:1442 E:1445 ||| IN
tumors  ||| S:1445 E:1452 ||| NNS
that  ||| S:1452 E:1457 ||| WDT
reflect  ||| S:1457 E:1465 ||| VBP
different  ||| S:1465 E:1475 ||| JJ
clinical  ||| S:1475 E:1484 ||| JJ
behavior ||| S:1484 E:1492 ||| NN
.  ||| S:1492 E:1494 ||| .
These  ||| S:1494 E:1500 ||| DT
studies  ||| S:1500 E:1508 ||| NNS
will  ||| S:1508 E:1513 ||| MD
require  ||| S:1513 E:1521 ||| VB
large  ||| S:1521 E:1527 ||| JJ
numbers  ||| S:1527 E:1535 ||| NNS
of  ||| S:1535 E:1538 ||| IN
independent  ||| S:1538 E:1550 ||| JJ
samples  ||| S:1550 E:1558 ||| NNS
for  ||| S:1558 E:1562 ||| IN
validation ||| S:1562 E:1572 ||| NN
.  ||| S:1572 E:1574 ||| .
Another  ||| S:1574 E:1582 ||| DT
approach  ||| S:1582 E:1591 ||| NN
has  ||| S:1591 E:1595 ||| VBZ
been  ||| S:1595 E:1600 ||| VBN
to  ||| S:1600 E:1603 ||| TO
identify  ||| S:1603 E:1612 ||| VB
genes  ||| S:1612 E:1618 ||| NNS
that  ||| S:1618 E:1623 ||| IN
correlate  ||| S:1623 E:1633 ||| NN
with  ||| S:1633 E:1638 ||| IN
patient  ||| S:1638 E:1646 ||| JJ
survival  ||| S:1646 E:1655 ||| NN
as  ||| S:1655 E:1658 ||| IN
a  ||| S:1658 E:1660 ||| DT
continuous  ||| S:1660 E:1671 ||| JJ
variable ||| S:1671 E:1679 ||| NN
.  ||| S:1679 E:1681 ||| .
These  ||| S:1681 E:1687 ||| DT
genes  ||| S:1687 E:1693 ||| NNS
are  ||| S:1693 E:1697 ||| VBP
then  ||| S:1697 E:1702 ||| RB
placed  ||| S:1702 E:1709 ||| VBN
into  ||| S:1709 E:1714 ||| IN
biologic  ||| S:1714 E:1723 ||| JJ
context  ||| S:1723 E:1731 ||| NN
using  ||| S:1731 E:1737 ||| VBG
pathway  ||| S:1737 E:1745 ||| JJ
analysis ||| S:1745 E:1753 ||| NN
.  ||| S:1753 E:1755 ||| .
These  ||| S:1755 E:1761 ||| DT
pathways  ||| S:1761 E:1770 ||| NNS
provide  ||| S:1770 E:1778 ||| VBP
potential  ||| S:1778 E:1788 ||| JJ
therapeutic  ||| S:1788 E:1800 ||| JJ
targets ||| S:1800 E:1807 ||| NNS
,  ||| S:1807 E:1809 ||| ,
and  ||| S:1809 E:1813 ||| CC
those  ||| S:1813 E:1819 ||| DT
patients  ||| S:1819 E:1828 ||| NNS
whose  ||| S:1828 E:1834 ||| WP$
tumors  ||| S:1834 E:1841 ||| NNS
express  ||| S:1841 E:1849 ||| VBP
these  ||| S:1849 E:1855 ||| DT
targets  ||| S:1855 E:1863 ||| NNS
may  ||| S:1863 E:1867 ||| MD
be  ||| S:1867 E:1870 ||| VB
most  ||| S:1870 E:1875 ||| RBS
effectively  ||| S:1875 E:1887 ||| RB
treated  ||| S:1887 E:1895 ||| VBN
by  ||| S:1895 E:1898 ||| IN
using  ||| S:1898 E:1904 ||| VBG
inhibitors  ||| S:1904 E:1915 ||| JJ
specific  ||| S:1915 E:1924 ||| JJ
for  ||| S:1924 E:1928 ||| IN
the  ||| S:1928 E:1932 ||| DT
pathway ||| S:1932 E:1939 ||| NN
.  ||| S:1939 E:1941 ||| .
There  ||| S:1941 E:1947 ||| EX
is  ||| S:1947 E:1950 ||| VBZ
a  ||| S:1950 E:1952 ||| DT
major  ||| S:1952 E:1958 ||| JJ
need  ||| S:1958 E:1963 ||| NN
for  ||| S:1963 E:1967 ||| IN
prognostic  ||| S:1967 E:1978 ||| NN
and  ||| S:1978 E:1982 ||| CC
predictive  ||| S:1982 E:1993 ||| JJ
biomarkers  ||| S:1993 E:2004 ||| NN
for  ||| S:2004 E:2008 ||| IN
ovarian  ||| S:2008 E:2016 ||| JJ
cancer ||| S:2016 E:2022 ||| NN
.  ||| S:2022 E:2024 ||| .
With  ||| S:2024 E:2029 ||| IN
the  ||| S:2029 E:2033 ||| DT
development  ||| S:2033 E:2045 ||| NN
of  ||| S:2045 E:2048 ||| IN
new  ||| S:2048 E:2052 ||| JJ
genomic  ||| S:2052 E:2060 ||| JJ
technologies ||| S:2060 E:2072 ||| NNS
,  ||| S:2072 E:2074 ||| ,
there  ||| S:2074 E:2080 ||| EX
is  ||| S:2080 E:2083 ||| VBZ
an  ||| S:2083 E:2086 ||| DT
opportunity  ||| S:2086 E:2098 ||| NN
to  ||| S:2098 E:2101 ||| TO
identify  ||| S:2101 E:2110 ||| VB
gene  ||| S:2110 E:2115 ||| NN
expression  ||| S:2115 E:2126 ||| NN
signatures  ||| S:2126 E:2137 ||| NNS
that  ||| S:2137 E:2142 ||| WDT
can  ||| S:2142 E:2146 ||| MD
be  ||| S:2146 E:2149 ||| VB
used  ||| S:2149 E:2154 ||| VBN
to  ||| S:2154 E:2157 ||| TO
stratify  ||| S:2157 E:2166 ||| VB
patients  ||| S:2166 E:2175 ||| NNS
according  ||| S:2175 E:2185 ||| VBG
to  ||| S:2185 E:2188 ||| TO
their  ||| S:2188 E:2194 ||| PRP$
ultimate  ||| S:2194 E:2203 ||| JJ
survival  ||| S:2203 E:2212 ||| NN
and  ||| S:2212 E:2216 ||| CC
response  ||| S:2216 E:2225 ||| NN
to  ||| S:2225 E:2228 ||| TO
chemotherapy ||| S:2228 E:2240 ||| VB
.  ||| S:2240 E:2242 ||| .
Large  ||| S:2242 E:2248 ||| JJ
independent  ||| S:2248 E:2260 ||| JJ
sets  ||| S:2260 E:2265 ||| NNS
and  ||| S:2265 E:2269 ||| CC
robust  ||| S:2269 E:2276 ||| JJ
statistical  ||| S:2276 E:2288 ||| JJ
techniques  ||| S:2288 E:2299 ||| NNS
will  ||| S:2299 E:2304 ||| MD
be  ||| S:2304 E:2307 ||| VB
required  ||| S:2307 E:2316 ||| VBN
to  ||| S:2316 E:2319 ||| TO
fully  ||| S:2319 E:2325 ||| RB
exploit  ||| S:2325 E:2333 ||| VB
this  ||| S:2333 E:2338 ||| DT
approach ||| S:2338 E:2346 ||| NN
.  ||| S:2346 E:2348 ||| .
